Semaglutide for early onset Type 1 diabetes – but a very small study…
In a small study involving only 10 people, semaglutide, a Type 2 drug, was given to people with Type 1 diabetes soon after the diagnosis. This led to no need for mealtime insulin in all patients and no need for basal insulin in most, along with improved glycaemic control. (The New England Journal of Medicine. September 2023)
Before building up our hopes, we have to recognise that this is a very small study and a much larger study is needed. In addition, we have to question whether there could be adverse effects.
